Arun Menawat Dr. Acquires 12,027 Shares of Profound Medical Corp. (TSE:PRN) Stock

Profound Medical Corp. (TSE:PRN) Director Arun Menawat Dr. bought 12,027 shares of the company’s stock in a transaction on Friday, May 16th. The stock was bought at an average cost of C$6.62 per share, with a total value of C$79,642.79.

Arun Menawat Dr. also recently made the following trade(s):

• On Thursday, May 15th, Arun Menawat Dr. purchased 10,003 shares of Profound Medical stock. The shares were acquired at an average price of C$6.06 per share, with a total value of C$60,568.17.
• On Friday, March 14th, Arun Menawat Dr. purchased 14,200 shares of Profound Medical stock. The shares were acquired at an average price of C$10.09 per share, with a total value of C$143,319.75.

Profound Medical Stock Up 5.9%

Shares of TSE:PRN opened at C$6.63 on Monday. Profound Medical Corp. has a one year low of C$5.58 and a one year high of C$15.75. The company has a debt-to-equity ratio of 20.05, a current ratio of 6.12 and a quick ratio of 14.98. The stock has a market cap of C$15.45 million, a price-to-earnings ratio of -3.44 and a beta of 1.22. The company has a 50 day moving average of C$7.48 and a 200-day moving average of C$9.38.

Analysts Set New Price Targets

Separately, Raymond James cut shares of Profound Medical from a “strong-buy” rating to a “moderate buy” rating in a research report on Friday, May 9th.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.